https://www.epiontx.com/news daily 0.75 2025-10-31 https://www.epiontx.com/news/fda-awards-fast-track-designation-to-epion-therapeutics-for-its-epismart-epithelium-on-cross-linking-system monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/4ba1957b-2b02-47a2-9468-c803f4a4977f/Fast+Track.png Press Releases - FDA Awards Fast Track Designation to Epion Therapeutics for its EpiSmart Epithelium-On Cross-Linking System - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/epion-therapeutics-announces-closing-of-financing-and-new-partnership-with-oculus monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1759864257327-9DYHNBGWA56SRZYK8R0N/Financing_OCULUS.png Press Releases - Epion Therapeutics Announces Closing of Financing & New Partnership with OCULUS - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/epion-therapeutics-announces-full-enrollment-in-apricity-phase-3-trials-for-epismart-epithelium-on-corneal-cross-linking monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/eda1916c-e0ea-419d-acc4-960f9df8829a/Enrollment+Complete.jpg Press Releases - Epion Therapeutics Announces Full Enrollment in Apricity Phase 3 Trials for EpiSmart® Epithelium-On Corneal Cross-Linking - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/epion-secures-new-us-patent-for-epismart-technology monthly 0.5 2025-10-31 https://www.epiontx.com/news/survey-of-us-optometrists-reveals-large-number-of-untreated-keratoconus-patients monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1729744860435-BN8R0JFRZHI3O7DSLI87/Template+for+LinkedIn+posts-2.jpg Press Releases - Survey of US Optometrists Reveals Large Number of Untreated Keratoconus Patients - Burlington, MA – April 8, 2024 – Epion Therapeutics’ Chief Medical Officer Michael W. Belin, MD, presented Phase 3 trial updates at Eyecelerator @ ASCRS 2024 on April 4th, 2024. During his presentation at Eyecelerator, Belin described the science behind Epion’s novel drug-device combination, EpiSmart, and updated attendees on enrollment in Epion’s Phase 3 Apricity studies. The Apricity studies focus on evaluating the efficacy and safety of EpiSmart, an investigational epithelium-on cross-linking system for keratoconus. This innovative treatment aims to strengthen corneal tissue without the need for chemical or mechanical disruption of the epithelium, potentially reducing patient discomfort and recovery time. https://www.epiontx.com/news/epion-therapeutics-cmo-michael-w-belin-md-shares-phase-3-updates-at-eyecelerator-during-ascrs-conference monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/f1eab9b7-2cd2-42a0-ae59-68a24a9b9790/Belin+Eyecelerator+%40+ASCRS+2024.png Press Releases - Epion Therapeutics' CMO, Michael W. Belin, MD, Shares Phase 3 Updates at Eyecelerator during ASCRS Conference - Burlington, MA – April 8, 2024 – Epion Therapeutics’ Chief Medical Officer Michael W. Belin, MD, presented Phase 3 trial updates at Eyecelerator @ ASCRS 2024 on April 4th, 2024. During his presentation at Eyecelerator, Belin described the science behind Epion’s novel drug-device combination, EpiSmart, and updated attendees on enrollment in Epion’s Phase 3 Apricity studies. The Apricity studies focus on evaluating the efficacy and safety of EpiSmart, an investigational epithelium-on cross-linking system for keratoconus. This innovative treatment aims to strengthen corneal tissue without the need for chemical or mechanical disruption of the epithelium, potentially reducing patient discomfort and recovery time. https://www.epiontx.com/news/epion-therapeutics-initiates-phase-3-clinical-trials-for-minimally-invasive-keratoconus-treatment-9j4c6 monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1699903844946-YU6GUYAYGVV0L5YPOXJB/Phase+3.png Press Releases - Epion Therapeutics Initiates Phase 3 Clinical Trials for Minimally-Invasive Keratoconus Treatment - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/cxl-ophthlamics-announces-new-name-and-vision-as-epion-therapeutics monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/800e2d65-c310-4106-bfff-4daa6e3d0b11/Announcing+Epion+GIF.gif Press Releases - CXL Ophthalmics Announces New Name and Vision as Epion Therapeutics - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/cxl-ophthalmics-ceo-michael-d-webb-to-present-at-2023-bio-international-convention monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1699903846854-AUYB1ZF3KYTO0NCLHT28/BIO%252B2023.jpg Press Releases - CXL Ophthalmics CEO Michael D. Webb to Present at 2023 BIO International Convention - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/beckman-ascrs-2023 monthly 0.5 2025-10-31 https://www.epiontx.com/news/ika2023 monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/71473c36-eb8d-4e1d-9702-f7751ec22109/1676762481830.jpeg Press Releases - CXL Ophthalmics’ CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/haynes monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/9a1cb580-b8d9-4c86-a960-706e3800e88e/Haynes+small.png Press Releases - CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations - Make it stand out Tiffany Haynes https://www.epiontx.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board monthly 0.5 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/923e4cd3-ca40-49b4-a557-fbd074c57eeb/JHT%2BHead%2BShot%2B042018.jpg Press Releases - CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Board - Make it stand out Jon Talamo, MD https://www.epiontx.com/news/cxl-ophthalmics-announces-32-million-series-a-investment-round-led-by-axa-im-alts-through-its-global-health-private-equity-strategy-8pant monthly 0.5 2025-10-31 https://www.epiontx.com/news/cxl-ophthalmics-publishes-results-of-epismart-cross-linking-phase-2-clinical-trial-for-keratoconus-in-cornea monthly 0.5 2025-10-31 https://www.epiontx.com/news/cxl-ophthalmics-announces-results-of-successful-phase-2-clinical-trial-in-epi-on-cross-linking-for-keratoconus-jtgjk monthly 0.5 2025-10-31 https://www.epiontx.com/news/cxl-ophthalmics-announces-patents-on-uv-a-device-for-transepithelial-epi-on-corneal-cross-linking-dyj5j monthly 0.5 2024-08-12 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1699903853450-BRJ0N49K7HDSO8SNUW7Q/uspto.jpg Press Releases - CXL Ophthalmics Granted Patents on UV-A Device for Transepithelial (Epi-on) Corneal Cross-linking - Proprietary light cycling features are optimized for cross-linking of intact, undisturbed cornea https://www.epiontx.com/news/cxl-ophthalmics-publishes-data-demonstrating-benefits-of-ribostat-for-transepithelial-cross-linking-xjk6s monthly 0.5 2024-08-12 https://www.epiontx.com/news/cxl-ophthalmics-appoints-jonathan-h-talamo-md-to-its-board-of-managers monthly 0.5 2024-08-12 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1699903855128-LYFHFIATYY4LOEF7PGXE/CXLO-logo.jpg Press Releases - CXL Ophthalmics Appoints Jonathan H. Talamo, MD to its Board of Managers Former Chief Medical Officer of Johnson & Johnson Vision, Ocular Therapeutix; Brings Wealth of Leadership and Global Strategic Experience https://www.epiontx.com/news/phase-2-enrollment monthly 0.5 2024-08-12 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1699903855128-LYFHFIATYY4LOEF7PGXE/CXLO-logo_highcontrast_margins.jpg Press Releases - Phase 2 Enrollment Complete - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/ribostat monthly 0.5 2024-08-12 https://www.epiontx.com/news/epismart-data-published monthly 0.5 2024-08-13 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1699903857395-EC1S6NMZU5AZ41M95P40/JCRS.jpg Press Releases - EpiSmart™ Clinical Data Published in JCRS - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.epiontx.com/news/epiprep-patent monthly 0.5 2024-08-12 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/24f3c98f-1ee8-4a35-b58a-c709374f0a90/European+Patent+Office.png Press Releases - EpiPrep™ Patent Is Issued https://www.epiontx.com/news/epismart-patent monthly 0.5 2024-08-12 https://www.epiontx.com/featured-articles daily 0.75 2026-03-06 https://www.epiontx.com/featured-articles/revised-analysis-reveals-pediatric-keratoconus-is-more-common-than-previously-reported monthly 0.5 2026-03-06 https://www.epiontx.com/featured-articles/phase-3-trials-in-focus-advances-in-cross-linking-for-keratoconus monthly 0.5 2026-01-14 https://www.epiontx.com/featured-articles/keratoconus-treatment-clinical-study-enrollment-deadline-ends-soon monthly 0.5 2024-10-04 https://www.epiontx.com/featured-articles/what-is-research-telling-us-about-cxl-in-kc monthly 0.5 2026-01-21 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/57a16ba7-270a-4a20-9087-075f50954d72/Eiden+Icon-4.png Featured Articles - Article Reviews Advances in Corneal Cross-Linking and the Importance of Early Keratoconus Treatment - Make it stand out S. Barry Eiden, OD, FAAO https://www.epiontx.com/featured-articles/ika-2024-importance-of-early-diagnostics-and-pediatric-screening-of-keratoconus monthly 0.5 2026-01-22 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/adecea4f-c530-428e-9667-f7b6ca5b2d46/Screenshot+2024-08-12+at+10.57.55%E2%80%AFPM.png Featured Articles - IKA 2024: Importance of early diagnostics and pediatric screening of keratoconus - Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium. Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium. https://www.epiontx.com/featured-articles/whats-on-the-horizon-for-keratoconus monthly 0.5 2026-01-22 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1723753829067-TOSYVNI5XR6JR25UQ3XN/unsplash-image-WukitUSJRgY.jpg Featured Articles - What’s on the Horizon for Keratoconus? - The number of keratoconus treatment options is growing, with new techniques and devices in development. Read the full article here https://www.epiontx.com/featured-articles/eyewiretv monthly 0.5 2026-01-22 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1723518250814-501T5OJ8FM80ILG9V1K5/Screenshot+2024-08-12+at+11.03.45%E2%80%AFPM.png Featured Articles - Video Interview: Michael W. Belin, MD, on Epion’s Phase 3 Epi-On Cross-Linking Trials - “What really makes the study unique is that we are treating the widest spectrum of disease.” Watch the interview here https://www.epiontx.com/featured-articles/the-epic-future-of-epi-on monthly 0.5 2026-01-22 https://www.epiontx.com/home daily 1.0 2026-03-06 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1695161909889-OVCG6PAZ2RWV6HCE9EVP/image-asset.jpeg https://www.epiontx.com/company daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1695154228283-KHUICQKS7OSP28MV4CIM/image-asset.jpeg https://www.epiontx.com/keratoconus daily 0.75 2025-11-05 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1695159526402-3GK4XU6U326419L8HTT4/image-asset.jpeg https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/1762375857454-TF7PBYWNY4TMRHSFZIVG/image-asset.jpeg https://www.epiontx.com/contact daily 0.75 2025-08-11 https://www.epiontx.com/team daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/fba36ddf-0e11-4a04-9c83-d3e9b50df26e/MikeWebb_WEB.jpg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/317aaef3-5889-45aa-a600-8ab328cbd3d5/EdParsons-sml.jpg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/b92f1a90-123c-4f3d-aab7-4f049eec26b8/Belin.jpg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/731021f2-a28c-489e-85bc-666ce07dc71d/Kevin%252BD%252BHead%252BShot.jpg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/c5f27d95-c5bf-45c4-85fd-152ab598154f/Haynes.jpeg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/923e4cd3-ca40-49b4-a557-fbd074c57eeb/JHT%2BHead%2BShot%2B042018.jpg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/4d992446-c2a0-40ff-9cb5-5d895df73389/LaBelle.jpeg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/e6efd6ab-fa01-4e83-b607-fe177895b382/MacDonald.jpg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/713e0d1f-087d-4088-aff3-0a966df3a4fa/MarcGOdrichMD.jpg Our Team https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/f8f2f4fc-1011-42db-b6ab-4a828d5abd89/Eiden.png Our Team https://www.epiontx.com/publications daily 0.75 2025-10-31 https://www.epiontx.com/press-releases-home daily 0.75 2025-11-05 https://www.epiontx.com/epismart daily 0.75 2026-03-06 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/e4933564-d404-440e-901d-c222f558abca/EpiPrepSystem.png https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/ca5e412b-d467-4edc-8821-c4aaf9edbcf0/Riboflavin.jpg https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/eaf9cfda-4c03-4ea0-8100-89144c715c5f/Screenshot+2023-09-19+at+4.55.09+PM.png https://www.epiontx.com/research daily 0.75 2025-11-05 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/39353b04-93cb-46ff-9657-6b8888094b1a/Figure+5+from+005 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/26c678f6-1c25-4f77-85e0-4c11619ba072/Stulting_JCRS2018.jpg https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/e83674b7-9d6d-42ac-b556-931fce0ee579/GGum_ARVO2019.png https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/02f67d74-fbb5-4df8-91ba-c4aa6db1a4ae/JCRS2018.png https://www.epiontx.com/webb daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/fba36ddf-0e11-4a04-9c83-d3e9b50df26e/MikeWebb_WEB.jpg https://www.epiontx.com/parsons daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/b9e6342a-dd78-40ae-8ca4-7cdd6a66c472/EdParsons-sml.jpg https://www.epiontx.com/belin daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/b92f1a90-123c-4f3d-aab7-4f049eec26b8/Belin.jpg https://www.epiontx.com/daly daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/731021f2-a28c-489e-85bc-666ce07dc71d/Kevin%252BD%252BHead%252BShot.jpg https://www.epiontx.com/haynes daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/c5f27d95-c5bf-45c4-85fd-152ab598154f/Haynes.jpeg https://www.epiontx.com/talamo daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/0d360e90-5f77-4ef0-b1bb-728355a99825/JHT%2BHi%2BRes%2BPhoto%2B2017.jpg https://www.epiontx.com/labelle daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/4d992446-c2a0-40ff-9cb5-5d895df73389/LaBelle.jpeg https://www.epiontx.com/macdonald daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/e6efd6ab-fa01-4e83-b607-fe177895b382/MacDonald.jpg https://www.epiontx.com/odrich daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/713e0d1f-087d-4088-aff3-0a966df3a4fa/MarcGOdrichMD.jpg https://www.epiontx.com/featured-articles-home daily 0.75 2026-01-16 https://www.epiontx.com/eiden daily 0.75 2025-10-31 https://images.squarespace-cdn.com/content/v1/6509ef8f4f02fc7d81317783/f8f2f4fc-1011-42db-b6ab-4a828d5abd89/Eiden.png https://www.epiontx.com/epismart-video daily 0.75 2024-08-31 https://www.epiontx.com/privacy-policy daily 0.75 2024-09-26 https://www.epiontx.com/recent-news daily 0.75 2025-10-14